Brief: Freeline Announces First Patient Dosed With Its Novel Gene Therapy Candidate For Gaucher Disease
26/06/2023 13:04
June 26 (Reuters) - Freeline Therapeutics Holdings PLC
FRLN.O :
* FREELINE ANNOUNCES FIRST PATIENT DOSED WITH ITS NOVEL GENE
THERAPY CANDIDATE FOR GAUCHER DISEASE AND UNVEILS RESEARCH
PROGRAM IN GBA1-LINKED PARKINSON’S DISEASE
* FREELINE THERAPEUTICS HOLDINGS PLC - EXPECTS TO REPORT
INITIAL
CLINICAL DATA FOR FLT201 IN Q3 OF 2023
Source text for Eikon: ID:nGNXVNsxb
Further company coverage: FRLN.O
((Reuters.Briefs@thomsonreuters.com;))